Key Points Bristol Myers Squibb's financial results haven't been great in recent years. The giant drugmaker has been facing challenges, including several patent cliffs. New launches, pipeline progress, and a dividend program still make it attractive. 10 stocks we like better than Bristol Myers Squibb › The past five years have been challenging for Bristol Myers Squibb (NYSE: BMY). The company lost patent exclusivity for some key products, including one that was once its best-selling medicine, can ...

Core Insights - Bristol Myers Squibb (BMY) shares increased by 5.62% following the announcement to continue the phase III ADEPT-2 study on Cobenfy for psychosis associated with Alzheimer's disease, contrary to investor expectations of a study failure [1][2][7] - The ADEPT-2 study's data readout has been postponed to next year, but the continuation of the study has reassured investors [2][7] - BMY's shares have declined by 9.9% year-to-date, while the industry has seen a growth of 19.9% [2] Study Details - The ADEPT-2 study is a multicenter, randomized, double-blind, placebo-controlled trial assessing the safety and efficacy of Cobenfy in patients with Alzheimer's disease dementia-related psychosis [4] - The primary endpoint focuses on changes in the Neuropsychiatric Inventory-Clinician Hallucinations and Delusions score, with a key secondary endpoint of Clinical Global Impression-Severity [5] - Irregularities were identified at a few study sites, leading to the exclusion of their data from the primary analysis after consultation with the FDA and a data monitoring committee (DMC) [6][7] Future Prospects - The DMC has recommended continuing the study by enrolling additional patients, and BMY will proceed with patient enrollment while remaining blinded to the study data [8] - Additional results from the ADEPT program, including ADEPT-1 and ADEPT-4, are expected by the end of 2026 [9] Portfolio Diversification - BMY is actively working to diversify its portfolio due to the negative impact of generics on its legacy drugs like Revlimid and Pomalyst [10] - The approval of Cobenfy has further diversified BMY's portfolio, with sales reaching $105 million year-to-date, and it is expected to be a significant growth driver as the company seeks label expansions [11] - The FDA has granted Fast Track Designation to BMS-986446, a potential anti-microtubule binding region-tau antibody currently in phase II development for early Alzheimer's disease [12]

Core Insights - Bristol-Myers Squibb Company (BMY) is a leading biopharmaceutical firm focused on innovative medicines for serious diseases, particularly in oncology, immunology, cardiovascular conditions, and blood disorders [1] - The company has a market capitalization of approximately $100.3 billion, positioning it in the large-cap category, which includes firms valued at $10 billion or more [2] Financial Performance - Over the past three months, BMY's stock has increased by about 4.3%, underperforming the S&P 500 Index, which returned 5.1% during the same period [3] - The stock reached a 52-week high of $63.33 in March but has since declined by roughly 22.2% [3] - In the last 12 months, BMY's shares have decreased by about 16.2%, and in 2025, they have fallen approximately 13% [4] Technical Analysis - BMY has recently approached its 200-day moving average after being below this level since April, indicating a potential shift in momentum [5] Revenue Challenges - The company faces challenges from generic competition affecting its older blockbuster drugs, including Revlimid, Pomalyst, Sprycel, and Abraxane [6] - In the Q3 earnings update on October 30, management reported a 12% year-over-year decline in revenue from its legacy portfolio, totaling $5.4 billion, primarily due to significant generic erosion in Revlimid [6]

Core Insights - Bristol Myers Squibb's growth portfolio performed strongly in Q3 2025, offsetting declines in legacy drug sales [1][8] - The growth portfolio includes key drugs such as Opdivo, Reblozyl, and Breyanzi, contributing significantly to revenue [1][4] Growth Portfolio Performance - Opdivo remains the top revenue generator, with strong sales driven by its launch in MSI-high colorectal cancer and growth in first-line non-small cell lung cancer in the U.S. [2] - Opdivo Qvantig's approval for subcutaneous use has enhanced the immuno-oncology portfolio, with projected global sales growth in the high single-digit to low double-digit range [3] - Reblozyl is annualizing over $2 billion in sales, driven by demand in various treatment settings [4] - Breyanzi sales have surpassed $1 billion, reflecting strong growth in large B-cell lymphoma [4] - Camzyos sales are increasing due to robust demand, and Cobenfy has shown encouraging initial uptake with $105 million in sales year to date [5] Competitive Landscape - The immuno-oncology market is competitive, with Merck's Keytruda dominating and accounting for around 50% of Merck's pharmaceutical sales [6] - Pfizer is also a significant player in oncology, with a diverse product portfolio including antibody-drug conjugates and biosimilars [7] Financial Performance and Valuation - Bristol Myers' shares have declined by 13.2% year to date, contrasting with the industry's growth of 15.9% [10] - The company is trading at a price/earnings ratio of 8.07x forward earnings, lower than its historical mean and the large-cap pharma industry's average of 16.42x [12] - The Zacks Consensus Estimate for 2025 earnings per share has remained unchanged, while estimates for 2026 have decreased [13]

Core Insights - Bristol Myers (BMY) has a robust oncology portfolio featuring key drugs such as Opdivo, Opdivo Qvantig, and Yervoy, which are crucial for the company's growth strategy [1][9] - Opdivo's sales in the U.S. are significantly driven by its successful launch in MSI-high colorectal cancer and ongoing growth in first-line non-small cell lung cancer, while international sales are supported by volume growth [2] - The European Commission approved the subcutaneous formulation of Opdivo for multiple solid tumor indications, enhancing its market presence [3] - Opdivo Qvantig has also received approval for subcutaneous use, with strong initial uptake in the U.S. across all indicated tumor types [4] - BMY anticipates global sales for Opdivo and Qvantig to grow in the mid to high single-digit range in 2025, supported by strong performance in the first half of the year [5] Competitive Landscape - The immuno-oncology market is highly competitive, with Merck's Keytruda and Roche's Tecentriq being significant competitors. Keytruda accounts for approximately 50% of Merck's pharmaceutical sales [6] - Roche's Tecentriq is approved for various oncology indications and has also received approval for subcutaneous administration, further intensifying competition [7] Financial Performance and Valuation - BMY's shares have declined by 13.6% year-to-date, contrasting with the industry's growth of 4.3% [8] - The company is trading at a price/earnings ratio of 7.60x forward earnings, which is below the industry average of 14.78x, indicating a potential undervaluation [10] - The bottom-line estimate for 2025 has increased to $6.50 from $6.41, while the estimate for 2026 has slightly decreased to $6.07 from $6.08 [11]

Group 1: Target - Target has faced a challenging year with subpar financial results, including a revenue decline and weak guidance, leading to a sell-off of its stock [4] - Economic uncertainty and a recent boycott related to diversity initiatives have compounded Target's difficulties, but the company is expected to weather these challenges [5] - Target has launched an Enterprise Acceleration Office to enhance productivity and efficiency, and its digital sales have shown growth, with a 4.7% increase in digital comparable sales [6][8] - The company's forward P/E ratio of 13.7 is attractive compared to the consumer staples average of 22.6, and it has a strong dividend profile with a yield of 4.6% [9][10] - Target is a Dividend King, having raised its payouts for 53 consecutive years, with a cash payout ratio of 45.7% [10] Group 2: Bristol Myers Squibb - Bristol Myers Squibb is facing significant patent cliffs, particularly for its top-selling cancer drug Opdivo, which will lose U.S. patent exclusivity in 2028 [11] - The company has developed a subcutaneous version of Opdivo, named Opdivo Qvantig, to extend its patent life, which has received FDA approval [12] - New product approvals, such as Reblozyl and Opdualag, have shown strong sales growth, with Reblozyl sales increasing by 35% year over year to $478 million [13] - Despite a 6% revenue decline to $11.2 billion in the first quarter, the company is expected to recover as newer products gain traction [14] - Bristol Myers Squibb offers a forward yield of 5.2% and has increased its payouts by 67.6% over the past decade, with a low forward P/E of 7 compared to the healthcare sector average of 16 [14][15]

Core Insights - Bristol-Myers Squibb Company participated in the 45th Annual TD Cowen Health Care Conference, highlighting its ongoing transformation and strong performance in 2024 [1][3] - The company emphasized the success of its growth portfolio, including products like Breyanzi, Camzyos, and Opdualag, which have shown exceptional performance [3][4] - A significant milestone for the company was the approval and launch of Cobenfy, marking the first new mechanism of action in schizophrenia treatment in decades, along with the approval of Opdivo Qvantig [4][5] Company Performance - The year 2024 was described as a pivotal year for the company, focusing on organizational transformation and delivering strong execution across its product portfolio [3] - The growth portfolio's performance was underscored, with specific mention of the successful products contributing to the company's overall success [3][4] Product Development - Cobenfy's approval and launch were highlighted as a key achievement, representing a significant advancement in schizophrenia treatment options [4] - The approval of Opdivo Qvantig at the end of the year was also noted as a critical development for the company [4][5]